How BRCA gene variants affect ovarian cancer treatment results
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study looks at how different BRCA gene changes affect how well ovarian cancer responds to treatment and the long-term outlook. If you were diagnosed with ovarian cancer and had BRCA testing at Bologna's S.Orsola hospital, your data could help researchers better understand treatment outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were diagnosed with ovarian cancer (but not the mucinous or borderline type) on or before December 31, 2021.
- You had a BRCA gene test at the Medical Genetics unit of the Bologna S.Orsola hospital by December 31, 2021.
- You received follow-up or treatment at the Medical Oncology or Gynecological Oncology units of the same hospital for at least one year (and up to December 31, 2021) and for at least 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at genetic changes in ovarian cancer to find possible targeted treatments. It may help you if you have certain types of ovarian cancer and are seeking more personalized care.
This study looks at certain “DNA repair traits” (called homologous recombination phenotype) in people with epithelial ovarian cancer. Results may help researchers better understand who responds to platinum chemotherapy, which is commonly used for this cancer.
This study collects tissue samples and medical information from people at higher risk for ovarian cancer or undergoing gynecologic surgery. Researchers use this data to develop better ways to detect and prevent ovarian cancer early.
This study follows women who carry gene mutations that increase ovarian cancer risk to understand how preventive surgery affects their health, quality of life, and peace of mind. Researchers will track your outcomes over 3 years to help inform future treatment decisions for others at similar risk.
This study looks for specific gene mutations in the blood of ovarian cancer patients who have a BRCA mutation and are starting first-line maintenance therapy with a PARP inhibitor called Olaparib. It aims to better understand how these mutations may affect treatment response.
This study looks at tumor tissue from ovarian cancer patients to find “biomarkers,” or lab signals, that may predict how the disease behaves or how it might respond to treatment. You may be asked for a biopsy of the relapsed (coming back) tumor or to use an existing archived tumor sample.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.